Why nearly 700 US medicines hinge on China-only raw materials

China-dependent chemicals threaten drug supply

A comprehensive review of supply-chain filings finds that hundreds of approved medicines in the United States rely on at least one key chemical that is produced only in China. This isn’t a niche corner of the market. Everyday antibiotics like amoxicillin, common antihistamines sold under familiar brands, and generics for heart disease, seizures, cancer and HIV all trace back to China-only inputs at the very start of the manufacturing chain. The finding matters because problems at that earliest stage—long before a pill is pressed or a vial is filled—can ripple through to pharmacies months later, the New York Times reported.

How the “first mile” became the weak link

Drug making is a relay race. The first runner handles key starting materials and intermediates—the basic chemicals that later become active pharmaceutical ingredients and finished doses. Over decades, production of those chemicals clustered in China thanks to cost advantages, scale, and looser pollution rules. Later stages often happen in India, Europe or North America, but if the baton is dropped in the first mile, the rest of the race slows or stops. That’s why a single outage at a Chinese facility, a pandemic shutdown, or an export hiccup can quietly seed a shortage half a world away.

From factory hiccup to pharmacy shelf

Shortages often begin as chemistry problems rather than end-market demand. When a China-only intermediate goes offline, API output falls, contract manufacturers idle capacity, and distributors draw down inventories. By the time patients encounter “out of stock,” the underlying issue may be a months-old disruption in a feedstock few people outside the supply chain have ever heard of. This lag makes shortages feel sudden even when their causes are upstream and predictable.

Where tariffs and geopolitics collide with medicine

Trade policy is another source of uncertainty. New or threatened US tariffs on Chinese goods are crafted for leverage, not for pharmaceutical stability. Even if finished generics are spared, levies on raw materials can raise costs for APIs and, eventually, finished doses. Manufacturers can cushion the blow with inventory and contracts, but prolonged tariffs tend to either lift prices or drive marginal suppliers from low-margin markets—both outcomes that can worsen shortages. A broader trade rift can also prompt China to curtail exports of specialized chemicals, adding a non-price risk on top of any duties.

Why new US plants don’t solve the core risk—yet

Announcements of billion-dollar facilities at home are real and welcome, but most target later steps such as fill-finish, packaging, or select APIs for flagship products. The first-mile chemistry remains commercially tough in the United States given energy, labour, compliance costs and hazardous-waste handling. Rebuilding that layer requires more than capital expenditure: it needs faster permits, predictable demand signals, specialized skills, and environmental infrastructure. Until those pieces are in place, the supply chain will keep looping back to China for critical ingredients.

What meaningful resilience would look like

De-risking the drug supply starts with visibility. Regulators and buyers need to know when a medicine depends on a single-country source for a key starting material. With clearer maps of those chokepoints, targeted incentives can encourage first-mile production in the US or allied countries, not just final-dose capacity. Friend-shoring with partners in India, the EU, Japan or South Korea can spread risk, especially if inspection regimes are aligned so new sites can come online quickly. Strategic stockpiles of essential intermediates and APIs—managed with strict quality controls and rotated to avoid expiry—can buffer shocks. And faster, predictable pathways for qualifying additional suppliers of shortage-prone generics can keep competitive redundancy alive.

The takeaway for patients and payers

America can make a lot of medicines at home and among allies, but too many of those products still begin with a China-only chemical. That’s a practical vulnerability, not an abstract one. Until the first mile is diversified, the system will remain exposed to factory outages, policy shocks and price creep that start far from the pharmacy counter yet end with patients and hospitals scrambling for basics.